Atenolol treatment for severe Infantile Hemangiomas: a single-centre prospective study
| Autor: | Talia Kakourou, George P. Chrousos, Alexis Alexopoulos, E. Georgiadou, I. Thanopoulou, Maria Dakoutrou |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Dermatology Propranolol Hemangioma 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Sensory Functions medicine Humans 030212 general & internal medicine Prospective Studies Prospective cohort study business.industry Incidence (epidemiology) Infant medicine.disease Disfigurement Atenolol Adrenergic beta-1 Receptor Antagonists Surgery Single centre Infectious Diseases Treatment Outcome Female business medicine.drug |
| Zdroj: | Journal of the European Academy of Dermatology and Venereology : JEADV. 32(3) |
| ISSN: | 1468-3083 |
| Popis: | Infantile hemangiomas (IHs) are common benign vascular tumors of infancy with an incidence of 4-5% 1. The majority of IHs are self-limited, though in approximately 10% of patients, when their lesions compromise vital and sensory functions or cause disfigurement, medical treatment is warranted 2,3. Τhe most exciting development in the treatment for IHs over the last decade has been the discovery of propranolol's effects during the proliferative phase of the hemangioma cycle 4. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text